Cargando…
The Different Pathways of Epicardial Adipose Tissue across the Heart Failure Phenotypes: From Pathophysiology to Therapeutic Target
Epicardial adipose tissue (EAT) is an endocrine and paracrine organ constituted by a layer of adipose tissue directly located between the myocardium and visceral pericardium. Under physiological conditions, EAT exerts protective effects of brown-like fat characteristics, metabolizing excess fatty ac...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095298/ https://www.ncbi.nlm.nih.gov/pubmed/37047810 http://dx.doi.org/10.3390/ijms24076838 |
_version_ | 1785024050306744320 |
---|---|
author | Rossi, Valentina A. Gruebler, Martin Monzo, Luca Galluzzo, Alessandro Beltrami, Matteo |
author_facet | Rossi, Valentina A. Gruebler, Martin Monzo, Luca Galluzzo, Alessandro Beltrami, Matteo |
author_sort | Rossi, Valentina A. |
collection | PubMed |
description | Epicardial adipose tissue (EAT) is an endocrine and paracrine organ constituted by a layer of adipose tissue directly located between the myocardium and visceral pericardium. Under physiological conditions, EAT exerts protective effects of brown-like fat characteristics, metabolizing excess fatty acids, and secreting anti-inflammatory and anti-fibrotic cytokines. In certain pathological conditions, EAT acquires a proatherogenic transcriptional profile resulting in increased synthesis of biologically active adipocytokines with proinflammatory properties, promoting oxidative stress, and finally causing endothelial damage. The role of EAT in heart failure (HF) has been mainly limited to HF with preserved ejection fraction (HFpEF) and related to the HFpEF obese phenotype. In HFpEF, EAT seems to acquire a proinflammatory profile and higher EAT values have been related to worse outcomes. Less data are available about the role of EAT in HF with reduced ejection fraction (HFrEF). Conversely, in HFrEF, EAT seems to play a nutritive role and lower values may correspond to the expression of a catabolic, adverse phenotype. As of now, there is evidence that the beneficial systemic cardiovascular effects of sodium-glucose cotransporter-2 receptors-inhibitors (SGLT2-i) might be partially mediated by inducing favorable modifications on EAT. As such, EAT may represent a promising target organ for the development of new drugs to improve cardiovascular prognosis. Thus, an approach based on detailed phenotyping of cardiac structural alterations and distinctive biomolecular pathways may change the current scenario, leading towards a precision medicine model with specific therapeutic targets considering different individual profiles. The aim of this review is to summarize the current knowledge about the biomolecular pathway of EAT in HF across the whole spectrum of ejection fraction, and to describe the potential of EAT as a therapeutic target in HF. |
format | Online Article Text |
id | pubmed-10095298 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100952982023-04-13 The Different Pathways of Epicardial Adipose Tissue across the Heart Failure Phenotypes: From Pathophysiology to Therapeutic Target Rossi, Valentina A. Gruebler, Martin Monzo, Luca Galluzzo, Alessandro Beltrami, Matteo Int J Mol Sci Review Epicardial adipose tissue (EAT) is an endocrine and paracrine organ constituted by a layer of adipose tissue directly located between the myocardium and visceral pericardium. Under physiological conditions, EAT exerts protective effects of brown-like fat characteristics, metabolizing excess fatty acids, and secreting anti-inflammatory and anti-fibrotic cytokines. In certain pathological conditions, EAT acquires a proatherogenic transcriptional profile resulting in increased synthesis of biologically active adipocytokines with proinflammatory properties, promoting oxidative stress, and finally causing endothelial damage. The role of EAT in heart failure (HF) has been mainly limited to HF with preserved ejection fraction (HFpEF) and related to the HFpEF obese phenotype. In HFpEF, EAT seems to acquire a proinflammatory profile and higher EAT values have been related to worse outcomes. Less data are available about the role of EAT in HF with reduced ejection fraction (HFrEF). Conversely, in HFrEF, EAT seems to play a nutritive role and lower values may correspond to the expression of a catabolic, adverse phenotype. As of now, there is evidence that the beneficial systemic cardiovascular effects of sodium-glucose cotransporter-2 receptors-inhibitors (SGLT2-i) might be partially mediated by inducing favorable modifications on EAT. As such, EAT may represent a promising target organ for the development of new drugs to improve cardiovascular prognosis. Thus, an approach based on detailed phenotyping of cardiac structural alterations and distinctive biomolecular pathways may change the current scenario, leading towards a precision medicine model with specific therapeutic targets considering different individual profiles. The aim of this review is to summarize the current knowledge about the biomolecular pathway of EAT in HF across the whole spectrum of ejection fraction, and to describe the potential of EAT as a therapeutic target in HF. MDPI 2023-04-06 /pmc/articles/PMC10095298/ /pubmed/37047810 http://dx.doi.org/10.3390/ijms24076838 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Rossi, Valentina A. Gruebler, Martin Monzo, Luca Galluzzo, Alessandro Beltrami, Matteo The Different Pathways of Epicardial Adipose Tissue across the Heart Failure Phenotypes: From Pathophysiology to Therapeutic Target |
title | The Different Pathways of Epicardial Adipose Tissue across the Heart Failure Phenotypes: From Pathophysiology to Therapeutic Target |
title_full | The Different Pathways of Epicardial Adipose Tissue across the Heart Failure Phenotypes: From Pathophysiology to Therapeutic Target |
title_fullStr | The Different Pathways of Epicardial Adipose Tissue across the Heart Failure Phenotypes: From Pathophysiology to Therapeutic Target |
title_full_unstemmed | The Different Pathways of Epicardial Adipose Tissue across the Heart Failure Phenotypes: From Pathophysiology to Therapeutic Target |
title_short | The Different Pathways of Epicardial Adipose Tissue across the Heart Failure Phenotypes: From Pathophysiology to Therapeutic Target |
title_sort | different pathways of epicardial adipose tissue across the heart failure phenotypes: from pathophysiology to therapeutic target |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095298/ https://www.ncbi.nlm.nih.gov/pubmed/37047810 http://dx.doi.org/10.3390/ijms24076838 |
work_keys_str_mv | AT rossivalentinaa thedifferentpathwaysofepicardialadiposetissueacrosstheheartfailurephenotypesfrompathophysiologytotherapeutictarget AT grueblermartin thedifferentpathwaysofepicardialadiposetissueacrosstheheartfailurephenotypesfrompathophysiologytotherapeutictarget AT monzoluca thedifferentpathwaysofepicardialadiposetissueacrosstheheartfailurephenotypesfrompathophysiologytotherapeutictarget AT galluzzoalessandro thedifferentpathwaysofepicardialadiposetissueacrosstheheartfailurephenotypesfrompathophysiologytotherapeutictarget AT beltramimatteo thedifferentpathwaysofepicardialadiposetissueacrosstheheartfailurephenotypesfrompathophysiologytotherapeutictarget AT rossivalentinaa differentpathwaysofepicardialadiposetissueacrosstheheartfailurephenotypesfrompathophysiologytotherapeutictarget AT grueblermartin differentpathwaysofepicardialadiposetissueacrosstheheartfailurephenotypesfrompathophysiologytotherapeutictarget AT monzoluca differentpathwaysofepicardialadiposetissueacrosstheheartfailurephenotypesfrompathophysiologytotherapeutictarget AT galluzzoalessandro differentpathwaysofepicardialadiposetissueacrosstheheartfailurephenotypesfrompathophysiologytotherapeutictarget AT beltramimatteo differentpathwaysofepicardialadiposetissueacrosstheheartfailurephenotypesfrompathophysiologytotherapeutictarget |